DEPRESSION 4a: Measurement Based Care for Major Depression: Treatment Decisions and Tactics

NOTE: It is recommended that the following program(s) be completed prior to initiating this activity:

DEPRESSION 1: Screening and Monitoring in Primary Care Clinics Treating Underserved Patients: Depression as the Sixth Vital Sign 

DEPRESSION 2: Major Depressive Disorder Remission as a Goal: A Measurement-Based Approach

The identification of Major Depressive Disorder (MDD) is infrequent in the Primary Care setting; however, once routine screening processes for MDD have been successfully implemented, confirmation of a diagnosis of MDD may be readily achieved by conducting a diagnostic interview and utilizing standardized screening tools. Providers can properly screen and diagnose MMD, with ongoing measurement to confidently treat and monitor their patients’ progress. This training will provide content to improve the providers’ competence in diagnosing and treating depression, with a goal of remission.

Participants will also learn to apply the appropriate screening tool for ongoing assessment of the patient’s status and make corresponding adjustments in treatment.

Method of Participation

This activity is in a video and synchronized slides format with a closed captions option. A text and slides (PDF) viewing option is also available. References are linked to online resources.

To receive a maximum of 0.75 AMA PRA Category 1 Credit(s)™ you should:

  • View the presentations in this enduring material.
  • Complete the posttest (you must answer 4 out of 5 questions correctly).
  • Complete and submit the CME registration and evaluation forms.

The estimated time to complete this activity, including review of the materials, is 0.75 hours.

Hardware/software requirements: Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox, and Google Chrome.

If you have questions about the participation process, please e-mail the UT Southwestern Medical Center, cmeregistrations@utsouthwestern.edu or phone 214-648-3138.

Accreditation/Credit Designation

The UT Southwestern Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The UT Southwestern Medical Center designates this enduring material activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been designated by UT Southwestern Medical Center for 0.75 hour(s) of education in medical ethics and/or professional responsibility.

Term of Approval

March 2015 through March 2017. Original release date: March 2015.

Peer Review

In 2015, this continuing medical education online enduring material was reviewed by Nitin Budhwar, MD, University of Texas Southwestern Medical Center, Dallas, Texas. To ensure the continued scientific relevance of this enduring material, its content will be reviewed again in March, 2017.

Disclosures: Nothing to disclose.

Program Director

Robert Rege, MD
Professor of Surgery
Chairman, Office of Continuing Medical Education
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosure: Nothing to disclose

Disclaimer

This CME activity is designed for use by healthcare professionals for educational purposes only. Information and opinion offered by the contributors represent their viewpoints. Conclusions drawn by the participant should be derived from careful consideration of all available scientific information. Prescription information and use of medical devices should be undertaken only after confirmation of information by consulting the FDA-approved uses and information.

This CME activity has been planned to be well-balanced and objective in discussion of comparative treatment regimens, and the the activity format allows for the free scientific exchange of ideas. Information and opinions offered by the speakers represent their viewpoints. Conclusions drawn by the audience should be derived from careful consideration of all available scientific information.

Links are provided to other Internet sites solely for the convenience of users. Once you link to another site, you are subject to the site"s terms and conditions of use including copyright and licensing restrictions.

Disclosure

The UT Southwestern Medical Center makes every effort to develop CME activities that are scientifically based, accurate, current, and objectively presented. In accordance with the Accreditation Council for Continuing Medical EducationStandards for Commercial Support™ the UT Southwestern Medical Center has implemented a mechanism requiring everyone in a position to control the content of an educational activity (e.g., directors, planning committee members, contributors, peer reviewers) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships: 1) at the time of the activity or within 12 months prior; and 2) of their spouses/partners.

The UT Southwestern Medical Center does not view the existence of interests or relationships with commercial entities as implying bias or decreasing the value of a presentation. It is up to the participants to determine whether the interests or relationships influence the presenter with regard to exposition or conclusions.

If at any time during this activity you feel that there has been commercial or promotional bias, please inform us by using the commercial bias comments box in the evaluation form. Please answer the questions about balance in the CME activity evaluation candidly.

The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:

Madhukar H. Trivedi, M.D., Faculty/Presenter/Contributor (Content Development)
Betty Jo Hay Distinguished Chair in Mental Health
Professor of Psychiatry
Director Comprehensive Center for Depression
Department of Psychiatry
University of Texas Southwestern Medical Center
Dallas, Texas

Disclosure: Consulting: Madhukar H. Trivedi is or has been an advisor/consultant to, Alkermes, AstraZeneca, Bristol-Myers Squibb Company, Cephalon, Inc., Cerecor, Concert Pharmaceuticals, Inc., Eli Lilly & Company, Evotec, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Global Services, LLC/Janssen Pharmaceutica Products, LP/Johnson & Johnson PRD, Lundbeck, MedAvante, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America, Inc., Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Pfizer Inc., Phoenix Marketing Solutions, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products Ltd ., Sepracor, SHIRE Development, Sunovion, Takeda, Vivus, and Wyeth-Ayerst Laboratories.

Research Activities: In addition, he has received research support from: Agency for Healthcare Research and Quality (AHRQ), National Alliance for Research in Schizophrenia and Depression, National Institute of Mental Health, National Institute on Drug Abuse, National Institute of Diabetes and Digestive Disorders.

Formal Advisory: Member, Scientific Advisory Board for the Canadian Biomarker Integration Network for Depression (CAN BIND) project (2014). Special Emphasis Panel, ZMH1 ERB – I (04), National Institute of Mental Health (NIMH), Mentored Career Development Award to Build Research Capacity in Global Mental Health, April 9, 2014.

The following individual(s) has/have reported no financial or other relationships with commercial entities whose products/services may relate to the educational content of this activity:

Nitin Budhwar, M.D., Peer Reviewer
Associate Professor
Family & Community Medicine
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosure: Nothing to disclose

Sara Levinson Eidelman, MPH, MSLOC, Contributor (Content Development)
VitalSign6 Project Manager
Mood Disorders Research Program and Clinic
Department of Psychiatry
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosure: Nothing to disclose

Ericka Harden-Dews, J.D., CHCP, CME Staff
Interim Director
Office of Continuing Medical & Public Education
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosure: Nothing to disclose

Tiffany Huggins, BSN, RN, (Content Development)
VitalSign6 Clinical Operations Manager
Mood Disorders Research Program and Clinic
Department of Psychiatry
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosure: Nothing to disclose

Deborah Phillips, B.S.N., RN, M.P.H., CME Staff
CE Program Coordinator
Office of Continuing Medical & Public Education
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosure: Nothing to disclose

Ronny Pipes, MA, LPC, Presenter/Contributor (Content Development)
VitalSign6 & Clinical Research Coordinator
Department of Psychiatry
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosure: Nothing to disclose

Joseph Trombello, Ph.D., Contributor (Content Development)
VitalSign6 Consulting Clinician
Department of Psychiatry
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosure: Nothing to disclose

Some drugs/devices identified during this activity may have United States Food and Drug Administration (FDA) clearance for specific purposes only or for use in restricted research settings. The FDA has stated that it is the responsibility of the individual physician to determine the FDA status of each drug or device that he/she wishes to use in clinical practice and to use the products in compliance with the applicable law.

The UT Southwestern Medical Center requires that all contributors disclose an unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products, and provide adequate scientific and clinical justification for such use. Physicians are urged to fully review all the available data on products or procedures before using them to treat patients.

Target Audience

This CME activity is designed to meet the educational needs of primary care physicians, nurse practitioners, and physician assistants, particularly those serving underserved and vulnerable populations.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Recognize the relevant background information needed from a patient, including past treatment history and general medical conditions
  • Employ the tactics of measurement based care for depression
  • Integrate critical decision points with patient response
  • Distinguish between phases of treatment
  • Recognize the paradigm that full remission is the goal of treatment
Course summary
Available credit: 
  • 0.75 AMA
  • 0.75 Attendance
Course opens: 
09/01/2014
Course expires: 
09/30/2016
Cost:
$0.00

Sara Levinson Eidelman, MPH, MSLOC, Contributor (Content Development)
VitalSign6 Project Manager
Mood Disorders Research Program and Clinic
Department of Psychiatry
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosure: Nothing to disclose

Ronny Pipes, MA, LPC, Presenter/Contributor (Content Development)
VitalSign6 & Clinical Research Coordinator
Department of Psychiatry
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosure: Nothing to disclose

Madhukar H. Trivedi, M.D., Faculty/Presenter/Contributor (Content Development)
Betty Jo Hay Distinguished Chair in Mental Health
Professor of Psychiatry
Director Comprehensive Center for Depression
Department of Psychiatry
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosure: Consulting: Madhukar H. Trivedi is or has been an advisor/consultant to, Alkermes, AstraZeneca, Bristol-Myers Squibb Company, Cephalon, Inc., Cerecor, Concert Pharmaceuticals, Inc., Eli Lilly & Company, Evotec, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Global Services, LLC/Janssen Pharmaceutica Products, LP/Johnson & Johnson PRD, Lundbeck, MedAvante, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America, Inc., Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Pfizer Inc., Phoenix Marketing Solutions, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products Ltd ., Sepracor, SHIRE Development, Sunovion, Takeda, Vivus, and Wyeth-Ayerst Laboratories.

Research Activities: In addition, he has received research support from: Agency for Healthcare Research and Quality (AHRQ), National Alliance for Research in Schizophrenia and Depression, National Institute of Mental Health, National Institute on Drug Abuse, National Institute of Diabetes and Digestive Disorders.

Formal Advisory: Member, Scientific Advisory Board for the Canadian Biomarker Integration Network for Depression (CAN BIND) project (2014). Special Emphasis Panel, ZMH1 ERB – I (04), National Institute of Mental Health (NIMH), Mentored Career Development Award to Build Research Capacity in Global Mental Health, April 9, 2014.

Joseph Trombello, Ph.D., Contributor (Content Development)
VitalSign6 Consulting Clinician
Department of Psychiatry
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosure: Nothing to disclose

Available Credit

  • 0.75 AMA
  • 0.75 Attendance

Accreditation Period

Course opens: 
09/01/2014
Course expires: 
09/30/2016

Price

Cost:
$0.00
Please login or create an account to take this course.

Required Hardware/software

Hardware/software requirements: Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox, and Google Chrome.